Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells

Prostate

Volumn 69, Issue 7, 2009, Pages 774-786

  Fernández Martínez, Ana B ^a   Bajo, Ana M ^a   Sánchez Chapado, Manuel ^a,b   Prieto, Juan C ^a   Carmena, María J ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

LNCaP and PC3 cells; Metastatic cascade; Prostate cancer; VIP

Indexed keywords

ANDROGEN; CURCUMIN; CYCLIN D1; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; UVOMORULIN; VASOACTIVE INTESTINAL POLYPEPTIDE; ANTIINFLAMMATORY AGENT; CADHERIN; MEMBRANE PROTEIN; RECK PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ZYMOGRAPHY; BIOSYNTHESIS; CELL GROWTH; CELL MOTION; CONFOCAL MICROSCOPY; DRUG EFFECT; EXTRACELLULAR MATRIX; MALE; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANTI-INFLAMMATORY AGENTS; CADHERINS; CELL ADHESION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CURCUMIN; CYCLIN D1; EXTRACELLULAR MATRIX; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE GLYCOPROTEINS; MICROSCOPY, CONFOCAL; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; VASOACTIVE INTESTINAL PEPTIDE;

EID: 65449178094     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20930     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Arya M, Bott SR, Shergill IS, Ahmed HU, Williamson M, Patel H. The metastatic cascade in prostate cancer. Surg Oncol 2006;15:117-128. (Pubitemid 46241866)
3. Mol AJ, Geldof AA, Meijer GA, van der Poel HG, van Moorselaar RJ. New experimental markers for early detection of high-risk prostate cancer: Role of cell-cell adhesion and cell migration. J Cancer Res Clin Oncol 2007;133:687-695.
4. Wang C, Li Z, Fu M, Bouras T, Pestell RG. Signal transduction mediated by cyclin D1: From mitogens to cell proliferation: A molecular target with therapeutic potential. Cancer Treat Res 2004;119:217-237.
5. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: Normal and abnormal functions. Endocrinology 2004;145:5439-5447.
6. Chin D, Boyle GM, Kane AJ, Theile DR, Hayward NK, Parson PG, Coman WB. Invasion and metastasis markers in cancers. Br J Plast Surg 2005;58:466-474. (Pubitemid 40645385)
7. Rubin MA, Mucci NR, Figurski J, Fecko A, Pienta KJ, Day ML. E-cadherin expression in prostate cancer: A broad survey using high-density tissue microarray technology. Hum Pathol 2001;32:690-697.
8. Köksal IT, Ozcan F, Kiliçaslan I, Tefekli A. Expression of E-cadherin in prostate cancer in formalin-fixed, paraffin-embedded tissues: Correlation with pathological features. Pathology 2002;34:233-238.
9. Slater MD, Lauer C, Gidley-Baird A, Barden JA. Markers for the development of early prostate cancer. J Pathol 2003;199:368-377. (Pubitemid 36266860)
10. Van Oort IM, Tomita K, van Bokhoven A, Bussemakers MJ, Kiemeney LA, Karthaus HF, Witjes JA, Schalken JA. The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: A long-term follow-up study. Prostate 2007;67:1432-1438.
11. Sternberg CN. Highlights of contemporary issues in the medical management of prostate cancer. Crit Rev Oncol Hematol 2002;43:105-121.
12. Vilches J, Salido M, Fernández-Segura E, Roomans GM. Neuropeptides, apoptosis and ion changes in prostate cancer. Methods of study and recent developments. Histol Histopathol 2004;19:951-961.
13. Vane JR, Bakhle YS, Botting RM. Cyclooxigenases 1 and 2. Ann Rev Pharmacol Toxicol 1998;38:97-120.
14. Miyamoto H, Altuwaijri S, Cai Y, Messing EM, Chang C. Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer. Mol Carcinog 2005;44:1-10.
15. Clark JCM, Thomas DM, Choong PFM, Dass CR. RECK - A newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev 2007;26:675-683. (Pubitemid 350115122)
16. Rabien A, Burkhardt M, Jung M, Fritzsche F, Ringsdorf M, Schicktanz H, Loening SA, Kristiansen G, Jung K. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy. Eur Urol 2007;51:1259-1266. (Pubitemid 46436286)
17. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, Marzo AM. Cyclooxigenases in cancer: Progress and perspective. Cancer Lett 2004;215:1-20.
18. Klein EA, Yang C, Kazanietz MG, Assoian RK. NFκB-independent signaling to the cyclin D1 gene by Rac. Cell Cycle 2007;6:1115-1121. (Pubitemid 46708585)
19. Simiantonaki N, Kurzik-Dumke U, Karyofylli G, Jayasinghe C, Kirkpatrick CJ. Loss of E-cadherin in the vicinity of necrosis in colorectal carcinomas: Association with NFκB expression. Int J Oncol 2007;31:269-275.
20. Bhandarkar SS, Arbiser JL. Curcumin as an inhibitor of angiogenesis. Adv Exp Med Biol 2007;595:185-195.
21. Vaalasti A, Tainio H, Pelto-Huikko M, Hervonen A. Light and electron microscope demonstration of VIP- and enkephalin-immunoreactive nerves in the human male genitourinary tract. Anat Rec 1986;215:21-27. (Pubitemid 16051555)
22. Collado B, Carmena MJ, Sánchez-Chapado M, Ruíz-Villaespesa A, Bajo AM, Fernández-Martínez AB, Varga JL, Schally AV, Prieto JC. Expression of vasoactive intestinal peptide (VIP) and functional VIP receptors in human prostate cancer: Antagonistic action of a growth-hormone-releasing hormone analog. Int J Oncol 2005;26:1629-1635.
23. Juarranz MG, Bolaños O, Gutiérrez-Cañas I, Lerner EA, Robberecht P, Carmena MJ, Prieto JC, Rodríguez-Henche N. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cell Signal 2001;13:887-894. (Pubitemid 33139790)
24. García-Fernández MO, Solano RM, Carmena MJ, Busto R, Bodega G, Ruíz-Villaespesa A, Prieto JC, Sánchez-Chapado M. Expression of functional PACAP/VIP receptors in human prostate cancer and healthy tissue. Peptides 2003;24:893-902. (Pubitemid 37011437)
25. Collado B, Gutiérrez-Cañas I, Rodríguez-Henche N, Prieto JC, Carmena MJ. Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regul Pept 2004;119:69-75. (Pubitemid 38482104)
26. Fernández-Martínez AB, Collado B, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-κB in human prostate cell lines. Differential time-dependent responses in cancer progression. Mol Cell Endocrinol 2007;270:8-16.
27. Gutiérrez-Cañas I, Juarranz MG, Collado B, Rodríguez-Henche N, Chiloeches A, Prieto JC, Carmena MJ. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK and PI3K. Prostate 2005;63:44-55. (Pubitemid 40365389)
28. 2+ signalling. Implications in angiogenesis and neuroendocrine differentiation. Biochim Biophys Acta 2005;1744:224-233.
29. Gutiérrez-Cañas I, Rodríguez-Henche N, Bolaños O, Carmena MJ, Prieto JC, Juarranz MG. VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. Br J Pharmacol 2003;139:1050-1058. (Pubitemid 36877404)
30. Collado B, Sánchez-Chapado M, Prieto JC, Carmena MJ. Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells. Mol Cell Endocrinol 2006;249:116-122.
31. Xie Y, Wolff DW, Lin MF, Tu Y. Vasoactive intestinal peptide transactivates the androgen receptor through a protein-kinase A-dependent extracelular signal-regulated kinase pathway in prostate cáncer LNCaP cells. Mol Pharmacol 2007;72:73-85. (Pubitemid 46998526)
32. Jongsma J, Oomen MH, Noordzij MA, Romijn JC, van der Kwast TH, Schröder FA, van Steenbrugge GJ. Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate 2000;42:34-44. (Pubitemid 30004873)
33. Jagetia GC, Aggarwal BB. "Spicing up" of theimmunesystem by curcumin. J Clin Immunol 2007;27:19-35.
34. Ekholm SV, Reed SI. Regulation of G(1) cyclin dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 2000;12:676-684.
35. Jamora C, Fuchs E. Intercellular adhesion, signaling and the cytoskeleton. Nat Cell Biol 2002;4:E101-E108.
36. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54:3929-3933. (Pubitemid 24241218)
37. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, Debruyne FM, Isaacs WB. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992;52:5104-5109.
38. Hableid JM, Nelson WJ. Cadherins in development: Cell adhesion, sorting and tissue morphogenesis. Genes Dev 2008;20:3199-3214.
39. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23. (Pubitemid 9239413)
40. Nagakawa O, Murata J, Junicho A, Matsuda T, Fujiuchi Y, Fuse H, Saiki I. Vasoactive intestinal peptide (VIP) enhances the cell motility of androgen receptor-transfected DU-145 prostate cancer cells (DU-145/AR). Cancer Lett 2002;176:93-99. (Pubitemid 34085074)
41. Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate Cancer Prostatic Dis 2003;6:217-222. (Pubitemid 37185149)
42. Zhang L, Shi J, Feng J, Klocker H, Lee C, Zhang J. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis 2004;7:327-332. (Pubitemid 41721791)
43. Aalinkeel R, Nair MPN, Sufrin G, Mahajan SD, Chadha KC, Chawda RP, Schwartz SA. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 2004;64:5311-5321. (Pubitemid 39006551)
44. Guan CX, Cui YR, Zhang M, Bai HB, Khunkhun R, Fang X. Intracellular signaling molecules involved in vasoactive intestinal peptide-mediated wound healing in human bronchial epithelial cells. Peptides 2007;28:1667-1673. (Pubitemid 47361439)
45. Grzmil M, Hemmerlein B, Thelen P, Schweyer S, Burfeind P. Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding proteins and suppresses MMP-2 expression. J Pathol 2004;202:50-59. (Pubitemid 38072845)
46. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion and metastasis. Oncogene 2001;20:4188-4197. (Pubitemid 32762193)
47. Hughes-Fulford M, Li CF, Boonyaratanakorukit J, Sayyah S. Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer. Cancer Res 2006;66:1427-1433 (Pubitemid 43259923)